CareLit · DOI-Nachweis · Aktuelle Neurologie
Combined regimen of temozolomide and liposomal pegylated doxorubicin in glioblastoma – toxicity and efficacy
DOI 10.1055/s-2005-919706
Bibliografische Angaben
Nachweis in CareLit
Autor:innenP Hau, T Jauch, U Baumgart, D Beier, S Gänßbauer, M Glas, B Hirschmann, H Koch, C Wismeth, A Steinbrecher, U Bogdahn
ZeitschriftAktuelle Neurologie
Ausgabe10/2005
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Temozolomide (Temodarä, TMZ) recently showed promising efficacy in an EORTC trial on first-line therapy of glioblastoma (Stupp R, 2005). Pegylated liposomal doxorubicin (Caelyxä, PEG-DOX) was evaluated in patients with recurrent high-grade glioma and showed an overall response rate of 40% (Hau P, 2002). Therefore, a combination of both agents seems promising. Methods: TMZ was given orally 75mg/m2 daily…
Zitieren
Zitierempfehlung
P Hau, T Jauch, U Baumgart, D Beier, S Gänßbauer, M Glas, B Hirschmann, H Koch, C Wismeth, A Steinbrecher, U Bogdahn (2005) Combined regimen of temozolomide and liposomal pegylated doxorubicin in glioblastoma – toxicity and efficacy. Aktuelle Neurologie (10). https://doi.org/10.1055/s-2005-919706
Mit CareLit weiterarbeiten